stent fracture after everolimus-eluting stent implantationeverolimus-eluting支架植入术后支架断裂.pdf

SAGE-Hindawi Access to Research Cardiology Research and Practice Volume 2011, Article ID 320983, 5 pages doi:10.4061/2011/320983 Case Report Stent Fracture after Everolimus-Eluting Stent Implantation ´ ˇ ´ Ali S. Almasood, Xavier Freixa, Sohail Q. Khan, Peter H. Seidelin, and Vladimır Dzavık Interventional Cardiology Program, Division of Cardiology, Peter Munk Cardiac Centre, University Health Network, University of Toronto, 6-246 EN, Toronto General Hospital, 200 Elizabeth Street, Toronto, ON, Canada M5G 2C4 ´ ˇ ´ Correspondence should be addressed to Vladimır Dzavık, vlad.dzavik@uhn.on.ca Received 29 November 2010; Accepted 6 February 2011 Academic Editor: Alexander Hirsch Copyright © 2011 Ali S. Almasood et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Compared with bare-metal stents, drug-eluting stents (DES) have greatly reduced the risk of in-stent restenosis (ISR) by inhibiting neointimal growth. Nevertheless, DES are still prone to device failure, which may lead to cardiac events. Recently, stent fracture (SF) has emerged as a potential mechanism of DES failure that is associated with ISR. Stent fracture is strongly related to stent type, and prior reports suggest that deployment of sirolimus eluting stents (SES) may be associated with a higher risk of SF compared to other DES. Everolimus eluting stents (EESs) represent a new generation of DES with promising results. The occurrence of SF with